QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bowles, T. M Articles by Levin, G. M Search for Related Content PubMed PubMed Citation Articles by Bowles, T. M Articles by Levin, G. M

NEW DRUG APPROVALS

Aripiprazole: A New Atypical Antipsychotic Drug

Psychopharmacology Fellow, Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL

Gary M Levin, PharmD BCPP FCCP

Professor and Chair, Department of Pharmacy Practice, School of Pharmacy, South University, Savannah, GA

Reprints: Gary M Levin PharmD BCPP FCCP, School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406-4805, FAX 912/201-8154, E-mail glevin{at}southuniversity.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of aripiprazole for the treatment of schizophrenia.

DATA SOURCES: Information was selected from MEDLINE (1995–August 2002). Abstracts, scientific posters, and presentations were also used.

STUDY SELECTION/DATA EXTRACTION: All published information regarding the pharmacokinetic, pharmacodynamic, and clinical characteristics of aripiprazole was considered. Studies providing a comprehensive description of aripiprazole were selected.

DATA SYNTHESIS: Aripiprazole is a dopamine partial agonist and a serotonin-2A antagonist; it is dosed 10–30 mg/d, with no initial titration necessary. Short-term clinical trials demonstrated efficacy in acute exacerbations, and long-term studies showed that aripiprazole can maintain remission of schizophrenia. Most adverse events were mild. The incidence of extrapyramidal symptoms was low, with akathisia being the most common.

CONCLUSIONS: Aripiprazole currently demonstrates comparable efficacy and safety for use in schizophrenia.

Key Words: aripiprazole, dopamine-system stabilizer, schizophrenia

Published Online, April 8, 2003. www.theannals.com, DOI 10.1345/aph.1C297

This article has been cited by other articles:

				H. Mulder, E. R Heerdink, E. E van Iersel, F. W Wilmink, and A. C. Egberts Prevalence of Patients Using Drugs Metabolized by Cytochrome P450 2D6 in Different Populations: a Cross-Sectional Study Ann. Pharmacother., March 1, 2007; 41(3): 408 - 413. [Abstract] [Full Text] [PDF]

				K. N Fountoulakis, M. Siamouli, S. Kantartzis, P. Panagiotidis, A. Iacovides, and G. S. Kaprinis Acute Dystonia with Low-Dosage Aripiprazole in Tourette's Disorder Ann. Pharmacother., April 1, 2006; 40(4): 775 - 777. [Abstract] [Full Text] [PDF]

				T. A. Rugino and Y. M. Janvier Aripiprazole in Children and Adolescents: Clinical Experience J Child Neurol, July 1, 2005; 20(7): 603 - 610. [Abstract] [PDF]

				A. M. Mortimer Another triumph of hope over experience?: REVISITING... TREATMENT OF THE PATIENT WITH LONG-TERM SCHIZOPHRENIA Advan. Psychiatr. Treat., July 1, 2005; 11(4): 277 - 285. [Abstract] [Full Text] [PDF]

				L. Citrome, R. Josiassen, N. Bark, D. E. Salazar, and S. Mallikaarjun Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate J. Clin. Pharmacol., January 1, 2005; 45(1): 89 - 93. [Abstract] [Full Text] [PDF]